Effects of Mesenchymal Stem Cell Transplantation on Spinal Cord Injury Patients

Overview

Journal Cell Tissue Res

Specialties Anatomy & Histology
Cell Biology

Date 2022 Jun 13

PMID 35697943

Authors

Fatemeh Tahmasebi

Shirin Barati

Affiliations

Soon will be listed here.

Abstract

Spinal cord injury (SCI) is a traumatic injury with sensory and motor deficits that more than 1 million patients worldwide suffer from disability due to it. Many pharmacological therapies help reduce SCI-related injury and protect CNS from more damage but no current therapy could improve the axonal repair. In this regard, stem cell therapy is considered a regenerative method for SCI patient treatment. The neurotrophic and immunomodulatory factor secretion, differentiation, neuroprotecting, and remyelinating properties have made mesenchymal stem cells (MSCs) principally useful in this field. There are studies on the role of MSCs in patients suffering from SCI. However, low number of SCI patients and the lack of control groups in these studies, the cell transplantation appropriate methods, including cell source, dose, route of delivery, and transplantation timing, are various in trials. This study reviews the beneficial effects of MSC transplantation in SCI clinical studies with a special focus on the MSC properties and limitations of MSC transplantation.

Citing Articles

Hypoxic-preconditioned mesenchymal stem cell-derived small extracellular vesicles inhibit neuronal death after spinal cord injury by regulating the SIRT1/Nrf2/HO-1 pathway.

Rao J, Xie H, Liang Z, Yang Z, Chen P, Zhou M Front Pharmacol. 2024; 15:1419390.

PMID: 39246654 PMC: 11377843. DOI: 10.3389/fphar.2024.1419390.

The combined application of stem cells and three-dimensional bioprinting scaffolds for the repair of spinal cord injury.

Ju D, Dong C Neural Regen Res. 2023; 19(8):1751-1758.

PMID: 38103241 PMC: 10960285. DOI: 10.4103/1673-5374.385842.

Mesenchymal Stem Cell Transplantation: Neuroprotection and Nerve Regeneration After Spinal Cord Injury.

Chen S, Yang R, Wu X, Zhao D, Fu S, Lin F J Inflamm Res. 2023; 16:4763-4776.

PMID: 37881652 PMC: 10595983. DOI: 10.2147/JIR.S428425.

Mesenchymal Stem Cell-Derived Extracellular Vesicles: An Emerging Diagnostic and Therapeutic Biomolecules for Neurodegenerative Disabilities.

Kandeel M, Morsy M, Alkhodair K, Alhojaily S Biomolecules. 2023; 13(8).

PMID: 37627315 PMC: 10452295. DOI: 10.3390/biom13081250.

Spinal cord injury: molecular mechanisms and therapeutic interventions.

Hu X, Xu W, Ren Y, Wang Z, He X, Huang R Signal Transduct Target Ther. 2023; 8(1):245.

PMID: 37357239 PMC: 10291001. DOI: 10.1038/s41392-023-01477-6.

References

Abdallah B, Haack-Sorensen M, Burns J, Elsnab B, Jakob F, Hokland P . Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite [corrected] extensive proliferation. Biochem Biophys Res Commun. 2004; 326(3):527-38. DOI: 10.1016/j.bbrc.2004.11.059. View

Albu S, Kumru H, Coll R, Vives J, Valles M, Benito-Penalva J . Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy. 2020; 23(2):146-156. DOI: 10.1016/j.jcyt.2020.08.008. View

Anderson K, Guest J, Dietrich W, Bunge M, Curiel R, Dididze M . Safety of Autologous Human Schwann Cell Transplantation in Subacute Thoracic Spinal Cord Injury. J Neurotrauma. 2017; 34(21):2950-2963. DOI: 10.1089/neu.2016.4895. View

Arboleda D, Forostyak S, Jendelova P, Marekova D, Amemori T, Pivonkova H . Transplantation of predifferentiated adipose-derived stromal cells for the treatment of spinal cord injury. Cell Mol Neurobiol. 2011; 31(7):1113-22. PMC: 11498601. DOI: 10.1007/s10571-011-9712-3. View

Bakshi A, Barshinger A, Swanger S, Madhavani V, Shumsky J, Neuhuber B . Lumbar puncture delivery of bone marrow stromal cells in spinal cord contusion: a novel method for minimally invasive cell transplantation. J Neurotrauma. 2006; 23(1):55-65. DOI: 10.1089/neu.2006.23.55. View

Bansal H, Verma P, Agrawal A, Leon J, Sundell I, Koka P . Autologous Bone Marrow-Derived Stem Cells in Spinal Cord Injury. J Stem Cells. 2017; 11(1):51-61. View

Barnabe-Heider F, Goritz C, Sabelstrom H, Takebayashi H, Pfrieger F, Meletis K . Origin of new glial cells in intact and injured adult spinal cord. Cell Stem Cell. 2010; 7(4):470-82. DOI: 10.1016/j.stem.2010.07.014. View

Bhanot Y, Rao S, Ghosh D, Balaraju S, Radhika C, Kumar K . Autologous mesenchymal stem cells in chronic spinal cord injury. Br J Neurosurg. 2011; 25(4):516-22. DOI: 10.3109/02688697.2010.550658. View

Boswell-Ruys C, Lewis C, Wijeysuriya N, McBain R, Lee B, McKenzie D . Impact of respiratory muscle training on respiratory muscle strength, respiratory function and quality of life in individuals with tetraplegia: a randomised clinical trial. Thorax. 2020; 75(3):279-288. DOI: 10.1136/thoraxjnl-2019-213917. View

10.

Libro R, Bramanti P, Mazzon E . The combined strategy of mesenchymal stem cells and tissue-engineered scaffolds for spinal cord injury regeneration. Exp Ther Med. 2017; 14(4):3355-3368. PMC: 5639409. DOI: 10.3892/etm.2017.4939. View

11.

Briquet A, Dubois S, Bekaert S, Dolhet M, Beguin Y, Gothot A . Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID-repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages. Haematologica. 2009; 95(1):47-56. PMC: 2805732. DOI: 10.3324/haematol.2009.008524. View

12.

Carlson K, Singh P, Feaster M, Ramnarain A, Pavlides C, Chen Z . Mesenchymal stem cells facilitate axon sorting, myelination, and functional recovery in paralyzed mice deficient in Schwann cell-derived laminin. Glia. 2010; 59(2):267-77. PMC: 3118468. DOI: 10.1002/glia.21099. View

13.

Caron I, Rossi F, Papa S, Aloe R, Sculco M, Mauri E . A new three dimensional biomimetic hydrogel to deliver factors secreted by human mesenchymal stem cells in spinal cord injury. Biomaterials. 2015; 75:135-147. DOI: 10.1016/j.biomaterials.2015.10.024. View

14.

Choo A, Liu J, Lam C, Dvorak M, Tetzlaff W, Oxland T . Contusion, dislocation, and distraction: primary hemorrhage and membrane permeability in distinct mechanisms of spinal cord injury. J Neurosurg Spine. 2007; 6(3):255-66. DOI: 10.3171/spi.2007.6.3.255. View

15.

Cummings B, Uchida N, Tamaki S, Salazar D, Hooshmand M, Summers R . Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice. Proc Natl Acad Sci U S A. 2005; 102(39):14069-74. PMC: 1216836. DOI: 10.1073/pnas.0507063102. View

16.

Dai G, Liu X, Zhang Z, Yang Z, Dai Y, Xu R . Transplantation of autologous bone marrow mesenchymal stem cells in the treatment of complete and chronic cervical spinal cord injury. Brain Res. 2013; 1533:73-9. DOI: 10.1016/j.brainres.2013.08.016. View

17.

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-7. DOI: 10.1080/14653240600855905. View

18.

El-Kheir W, Gabr H, Awad M, Ghannam O, Barakat Y, Farghali H . Autologous bone marrow-derived cell therapy combined with physical therapy induces functional improvement in chronic spinal cord injury patients. Cell Transplant. 2013; 23(6):729-45. DOI: 10.3727/096368913X664540. View

19.

Faulkner J, Keirstead H . Human embryonic stem cell-derived oligodendrocyte progenitors for the treatment of spinal cord injury. Transpl Immunol. 2006; 15(2):131-42. DOI: 10.1016/j.trim.2005.09.007. View

20.

Fawcett J, Curt A, Steeves J, Coleman W, Tuszynski M, Lammertse D . Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord. 2006; 45(3):190-205. DOI: 10.1038/sj.sc.3102007. View